博济医药(300404.SZ)：“FCZR”获得药物临床试验批准通知书

Core Viewpoint - The company Boji Pharmaceutical has received approval from the National Medical Products Administration for its clinical trial of the new drug "FCZR," which targets ear fungal infections and offers significant clinical advantages [1] Company Summary - Boji Pharmaceutical (300404.SZ) announced the approval of its clinical trial for "FCZR" [1] - FCZR is classified as a modified new drug of category 2.2/2.4, optimized in formulation, prescription process, administration route, and indications [1] - The intended indication for FCZR is ear fungal disease, a common infectious condition in otolaryngology, particularly prevalent in hot and humid seasons and regions [1] Industry Summary - Ear fungal disease is a frequently occurring infection that is often recurrent and difficult to cure [1] - The formulation of FCZR offers advantages in fluidity and ease of administration, allowing for direct contact with lesions in the ear canal through ear drops, thus enabling localized treatment [1] - Currently, there are no similar drugs approved for sale in both domestic and international markets, and there are no related sales data available [1]